Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2015-05-08 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive completes share issue raising SEK 70 million for the preparation of CicloMulsion®’s clinical trial in the US and commercialization in Europe
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces the completion of a directed share issue, detailing the amount raised (SEK 70 million), the number of new shares issued, and the intended use of proceeds (clinical trials and commercialization). This type of announcement, detailing fundraising and capital structure changes, directly aligns with the definition of a Capital/Financing Update (CAP). Although it mentions the authorization came from the AGM, the core content is the financing event itself, not the AGM materials (AGM-R) or a general regulatory filing (RNS). It is not a full annual report (10-K) or an earnings release (ER).
2015-05-08 English
NeuroVive planerar genomföra en riktad nyemission
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and dated 2015-05-07. The core subject is the plan to conduct a 'riktad nyemission' (directed new share issue/private placement) to raise capital for clinical trials and market launch preparation. This action directly relates to fundraising, financing activities, and capital structure changes. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). It is not a full 10-K, an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it details the specifics of the financing event itself.
2015-05-07 Swedish
NeuroVive announces the intention to raise additional capital through a private placement
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces the "intention to raise additional capital through a private placement." This action involves issuing new equity and changing the capital structure, which directly aligns with the definition of a Capital/Financing Update (CAP). Although it mentions the authorization from the AGM, the core purpose is the financing activity itself, not the AGM materials or voting results. It is not a full 10-K, an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific financing event.
2015-05-07 English
Första patienten inkluderad i fas II-studie för skydd mot akut njurskada vid hjärtoperation
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and is dated 2015-04-27. It announces a specific corporate event: the inclusion of the first patient in a Phase II clinical study for their product CicloMulsion®. This type of announcement, detailing operational progress, clinical trial milestones, and scientific background, is characteristic of a general corporate update or news release. It is not a full Annual Report (10-K), a formal Earnings Release (ER) focusing only on financial figures, or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Change (SHA). Since it is a press release announcing operational progress, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS), as it is a public disclosure required by market rules (as stated at the end: "NeuroVive Pharmaceutical AB (publ) är skyldigt att offentliggöra informationen i detta pressmeddelande enligt lagen om värdepappersmarknaden"). It is not an announcement *about* a report (RPA), but the report/update itself.
2015-04-27 Swedish
First patient enrolled in clinical phase II study for kidney protection during heart surgery
Regulatory Filings Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces a specific corporate event: the enrollment of the first patient in a Phase II clinical study for their product CicloMulsion®. This type of announcement, detailing operational progress, clinical trial updates, and market potential, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release announcing operational progress rather than a full financial report (10-K, IR) or a transcript (CT), the most fitting category is Earnings Release (ER), which often includes key operational highlights alongside financial context, or Regulatory Filings (RNS) if it's a mandatory disclosure. Given the content focuses heavily on clinical trial progress and market need, it functions as a key operational update often bundled with earnings information. However, because it is a general news release about a clinical milestone and not explicitly tied to quarterly financial results (though it is dated), and it is a formal disclosure required under securities law (mentioned at the end), it fits well under the general disclosure category. Since 'ER' is defined as the *initial announcement of periodical financial results (key highlights only)*, and this is a clinical highlight, 'RNS' (Regulatory Filings/General announcement) is a strong candidate. However, many companies issue these operational updates as part of their regular investor communications, often coinciding with or near earnings periods. Given the structure and content (a formal press release announcing a significant operational milestone), it is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if we assume operational updates are included. Since it is not a financial report itself, and it's a formal announcement, RNS is the safest general classification for non-standard disclosures. Upon review, many operational updates that are not strictly financial results announcements fall under RNS. I will select RNS as the most appropriate general regulatory disclosure category for a clinical trial update press release.
2015-04-27 English
Clinical Phase II study with NeuroSTAT® for traumatic brain injury passes safety evaluation
Regulatory Filings Classification · 1% confidence The document is explicitly titled and formatted as a "NEWS RELEASE" from NeuroVive Pharmaceutical AB, dated April 21, 2015. It announces the progress of a clinical study (Phase IIa for NeuroSTAT®) and provides an update on the status of several drug candidates (CicloMulsion®, NeuroSTAT®, NVP019, NVP018). This content structure—announcing key operational and clinical milestones via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on operational updates and clinical progress rather than just summarizing quarterly financial figures (which would be ER), and it is a formal announcement required under securities law ("The Swedish Securities Market Act"), it fits best as a general regulatory announcement or news release. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, non-standardized news release that isn't a core financial report (10-K, IR) or a specific management discussion (MDA). It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Financial Supplement (XLSX). It is an announcement, not the full report itself, making RPA less likely as it's not announcing the publication of a *different* report, but rather reporting news directly.
2015-04-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.